Management Strategy for Patients With Idiopathic Recurrent Pericarditis. Position Statement of the Experts of the Russian Society оf Cardiology and Eurasian Association of Therapists

Pericarditis as an inflammatory heart disease is rarely discussed in the cardiology community. The latest European guidelines on pericarditis were published in 2015, and Russian clinical guidelines are dated 2022. However, in recent years, a number of publications have appeared that have forced the scientific community to take a fresh look at this problem. This is mainly due to a change in the paradigm of the treatment of idiopathic recurrent pericarditis (IRP) registered in the Russian Federation as a rare (orphan) disease. According to most experts, IRP is an underestimated cardiac disease, which, due to the lack of specific symptoms and the physicians’ alertness regarding the IRP diagnostics, is rarely the subject of scientific discussions. The issues of diagnosis and therapy of IRP in light of the latest reports became the matter under discussion for a group of leading Russian experts chaired by Corresponding Member of the Russian Academy of Sciences, Professor G.P. Arutyunov.

1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921–64. DOI: 10.1093/eurheartj/ehv318

2. Arutyunov G.P., Paleev F.N., Tarlovskaya E.I., Moiseeva O.M., Arutyunov A.G., Koziolova N.A. et al. Pericarditis. Clinical Guidelines 2022. Russian Journal of Cardiology. 2023;28(3):107–67. DOI: 10.15829/1560-4071-2023-5398

3. Brucato A, Emmi G, Cantarini L, Di Lenarda A, Gattorno M, Lopalco G et al. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine. 2018;13(4):475–89. DOI: 10.1007/s11739-018-1842-x

4. Andreis A, Imazio M, Casula M, Avondo S, Brucato A. Recurrent pericarditis: an update on diagnosis and management. Internal and Emergency Medicine. 2021;16(3):551–8. DOI: 10.1007/s11739-021-02639-6

5. Imazio M, Lazaros G, Brucato A, Gaita F. Recurrent pericarditis: new and emerging therapeutic options. Nature Reviews Cardiology. 2016;13(2):99–105. DOI: 10.1038/nrcardio.2015.115

6. Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases. 2014;73(12):2160–7. DOI: 10.1136/annrheumdis-2013-204184

7. Bizzi E, Trotta L, Pancrazi M, Nivuori M, Giosia V, Matteucci L et al. Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments. Current Cardiology Reports. 2021;23(9):128. DOI: 10.1007/s11886-021-01549-5

8. Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, Aegisdottir HM, Oddsson A, Stefansson OA et al. Variants at the Interleukin 1 Gene Locus and Pericarditis. JAMA Cardiology. 2024;9(2):165–72. DOI: 10.1001/jamacardio.2023.4820

9. Klein A, Cremer P, Kontzias A, Furqan M, Tubman R, Roy M et al. US Database Study of Clinical Burden and Unmet Need in Recurrent Pericarditis. Journal of the American Heart Association. 2021;10(15):e018950. DOI: 10.1161/JAHA.120.018950

10. Myachikova V.Yu., Maslyanskiy A.L., Moiseeva O.M. Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis. Kardiologiia. 2021;61(1):72–7. DOI: 10.18087/cardio.2021.1.n1475

11. Imazio M, Nidorf M. Colchicine and the heart. European Heart Journal. 2021;42(28):2745–60. DOI: 10.1093/eurheartj/ehab221

12. Melendo-Viu M, Marchán-Lopez Á, Guarch CJ-L, Roubín SR, Abu-Assi E, Meneses RT et al. A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis. Trends in Cardiovascular Medicine. 2023;33(5):319–26. DOI: 10.1016/j.tcm.2022.02.001

13. Perrone A, Castrovilli A, Piazzolla G, Savino S, D’Introno A, Sabbà C. Corticosteroids for Acute and Recurrent Idiopathic Pericarditis: Unexpected Evidences. Cardiology Research and Practice. 2019;2019:1348364. DOI: 10.1155/2019/1348364

14. Vecchié A, Bonaventura A, Golino M, Thomas G, Abbate A. Novel Therapeutic Insights Into the Treatment of Pericarditis: Targeting the Innate Immune System. Journal of Cardiovascular Pharmacology. 2024;83(5):377–83. DOI: 10.1097/FJC.0000000000001553

15. Imazio M, Lazaros G, Gattorno M, LeWinter M, Abbate A, Brucato A et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. European Heart Journal. 2022;43(31):2946–57. DOI: 10.1093/eurheartj/ehab452

16. Lin D, Laliberté F, Majeski C, Magestro M, Lejeune D, Duh MS et al. Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population. Advances in Therapy. 2021;38(10):5127–43. DOI: 10.1007/s12325-021-01868-7

17. Imazio M, Andreis A, De Ferrari GM, Cremer PC, Mardigyan V, Maestroni S et al. Anakinra for corticosteroid-dependent and colchicineresistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. European Journal of Preventive Cardiology. 2020;27(9):956–64. DOI: 10.1177/2047487319879534